PCR-荧光探针法在泌尿生殖道沙眼衣原体感染诊断及治愈判断中的价值

The value of PCR-fluorescent probe in the diagnosis and estimation of cure rate of Chlamydia trachomatis infection in genitourinary tract inflammation

目的采用PCR-荧光探针法检测泌尿生殖道炎症患者沙眼衣原体(CT) DNA(CT-DNA),以了解浙江地区泌尿生殖道炎症患者沙眼衣原体感染情况及PCR-荧光探针法检测CT感染及疗效判断中的价值。方法选择2017年1月-2018年12月本院妇科门诊及皮肤性病科接诊的11 396例泌尿生殖道炎症患者为研究对象,PCR-荧光探针法检测CT-DNA阳性患者标本,采用阿奇霉素1 g顿服7 d连续服药治疗并完成随访,以临床症状消失为临床判愈标准,PCR-荧光探针法检测CT-DNA阴性为病原学判愈标准。结果 11 396例泌尿生殖道炎症患者CT-DNA阳性1 198例,感染率为10.5%,女性感染率(10.9%)明显高于男性(8.3%)(P <0.01);不同年龄段感染率差异大,<20岁感染率最高。临床症状消失914例、治愈率为76.3%,CT-DNA阴性885例、治愈率为73.9%,2种判愈标准治愈率差异无统计学意义(P> 0.05),结果一致率为95.0%。结论 PCR-荧光探针法是泌尿生殖道炎症患者沙眼衣原体感染检测及随访较为客观的病原学判愈方法,具有简便、快速和准确的优点,适合于临床推广应用。

Objective To detect Chlamydia trachomatis(CT)DNA in patients with genitourinary tract inflammation by PCR-fluorescent probe method,in order to understand the infection of CT and the cure rates in patients with genitourinary tract inflammation.Methods CT-DNA was detected in 11396 suspected genitourinary tract inflammation patients in our Hospital from January 2017 to December 2018 by PCR-fluorescent probe.1198 patients with CT infection diagnosed were treated with Azithromycin 1 g dosing once a day for 7 consecutive days treatment and followed up.The disappearance of clinical symptoms was defined as the clinical standard and the negative detection of CT-DNA in clinical samples by PCR-fluorescent probe was defined as the pathogenic standard.Results A total of 1198 were positive for CT-DNA,with a positive rate of 10.5%,and the infection rate of female(10.9%)was higher than that of male(8.3%).The infection rate was the highest in the age group of<20.According to the clinical standard,914 cases were cured,the cure rate was 76.3%,the cure rates of PCR-fluorescence probe were 73.9%(P>0.05),and the consistency rate of the two methods was 95.0%.Conclusion PCR-fluorescence probe methods is an objective method to detect and follow up Chlamydia trachomatis infection in patients with genitourinary tract inflammation.It is simple,rapid and accurate suitable for clinical promotion.